These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7658613)

  • 1. A novel modified t-PA, E-6010, induces faster recovery of ventricular function after coronary thrombolysis than native t-PA in a canine thrombosis model.
    Suzuki S; Saito M; Yui Y; Kawai C
    Jpn Circ J; 1995 Apr; 59(4):205-12. PubMed ID: 7658613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel modified tissue-type plasminogen activator (t-PA), E6010, gradually increases coronary blood flow after thrombolysis compared with native t-PA, urokinase and balloon catheter occlusion-reperfusion.
    Saito M; Suzuki S; Yui Y; Kawai C
    Jpn J Pharmacol; 1994 Sep; 66(1):17-23. PubMed ID: 7532243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel modified tissue-type plasminogen activator (t-PA), E6010, reduces reperfusion arrhythmias induced after coronary thrombolysis--comparison of native t-PA and urokinase.
    Saito M; Suzuki S; Yui Y; Kawai C
    Jpn Circ J; 1995 Aug; 59(8):556-64. PubMed ID: 7474300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity.
    Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Yui Y; Kawai C
    J Cardiovasc Pharmacol; 1993 Dec; 22(6):834-40. PubMed ID: 7509901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
    Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Mizuo H; Yuzuriha T; Yui Y; Kawai C
    J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombolytic effects of a novel modified tissue plasminogen activator, E6010, on coronary thrombosis in the pig.
    Adachi H; Nagaoka N; Nomoto K; Yuzuriha T; Shoji T
    Jpn J Pharmacol; 1992 Mar; 58(3):309-19. PubMed ID: 1513078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA. E6010 Study Group.
    Kawai C; Yui Y; Hosoda S; Nobuyoshi M; Suzuki S; Sato H; Takatsu F; Motomiya T; Kanmatsuse K; Kodama K; Yabe Y; Minamino T; Kimata S; Nakashima M
    J Am Coll Cardiol; 1997 Jun; 29(7):1447-53. PubMed ID: 9180103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolysis of canine femoral artery thrombus by a novel modified tissue-type plasminogen activator (E6010).
    Suzuki N; Suzuki S; Nagaoka N; Mizuo H; Yuzuriha T; Yoshitake S; Kanmatuse K
    Jpn J Pharmacol; 1994 Jul; 65(3):257-63. PubMed ID: 7799526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ventricular function and cardiac hypertrophy after coronary thrombolysis with tissue-type plasminogen activator (t-PA) in dogs with coronary artery thrombi.
    Suzuki M; Asano H; Kimoto A; Tanaka H; Usuda S
    J Pharm Pharmacol; 2000 Aug; 52(8):969-76. PubMed ID: 11007068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ; Follenfant MJ; Ford AJ
    Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
    Söhngen W; Mickelson JK; Simpson PJ; Lucchesi BR
    Thromb Res; 1988 Jul; 51(1):63-74. PubMed ID: 3137691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of time of 7E3 administration on rt-PA-induced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion.
    Rebello SS; Huang J; Saito K; Saucedo JF; Bates ER; Lucchesi BR
    Eur J Pharmacol; 1999 Jun; 374(3):399-410. PubMed ID: 10422784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low incidence of hemorrhagic infarction following coronary reperfusion with nasaruplase in a canine model of acute myocardial infarction. Comparison with recombinant t-PA.
    Kido H; Hayashi K; Uchida T; Watanabe M
    Jpn Heart J; 1995 Jan; 36(1):61-79. PubMed ID: 7760515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary reperfusion by thrombolysis and early beta-adrenergic blockade in acute experimental myocardial infarction.
    Jang IK; Van de Werf F; Vanhaecke J; De Geest H
    J Am Coll Cardiol; 1989 Dec; 14(7):1816-23. PubMed ID: 2511233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis.
    Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C
    Jpn J Pharmacol; 1993 Sep; 63(1):9-16. PubMed ID: 8271535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K; Kloner RA
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YM866, a novel modified tissue-type plasminogen activator, affects left ventricular function and myocardial infarct development in dogs with coronary artery thrombi.
    Suzuki M; Funatsu T; Tanaka H; Usuda S
    Jpn J Pharmacol; 1998 Jul; 77(3):177-83. PubMed ID: 9717764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.